Elevation Oncology Inc Stock News

-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload -- – Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologies AMSTERDAM , Dec. 12, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its ...

-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ) cancer – -- On-track to initiate dosing in combination portion of the ongoing Phase 1 clinical trial of EO-3021 in the fourth quarter of 2024 -- BOSTON , Dec. 5, 2024 /PRNewswire/ -- Elevation On...

BOSTON , Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, President and Chief Executive Officer of Elevation Oncology, will participate in a firesid...

-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 with ...

On September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,000,000 shares of Elevation Oncology Inc (ELEV, Financial). This transaction, executed at a price of $0.5999 per share, represents a notable increase in the firm's stake in the biotechnology company.

BOSTON , Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differe...

BOSTON , Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J.